Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Borrelidin: a novel therapeutic agent for treatment of inflammatory diseases.
EF 2009-10
Résumé
Inflammation is the body's normal physiological response to injury, infection, or foreign substances. Although the ability to mount an inflammatory response is essential for survival, uncontrolled or excessive inflammatory responses damage tissues, cause organ dysfunction, and require clinical intervention. Despite the fact there have been advances in anti-inflammatory therapies over the years, long term use of steroidal and non-steroidal anti-inflammatory drugs (NSAIDS) are limited due to drug-induced toxicities such as stomach ulcer, gastric erosion, exacerbation of asthma and nephrotoxicity. Therefore, the identification of novel agents that can effectively suppress inflammatory responses without associated long term toxicities for treatment of chronic inflammatory diseases represents a major unmet medical need. To identify new anti-inflammatory drugs, we looked to nature for inspiration. One of the key ways that the body controls inflammation is through the expression of immunoregulatory enzymes. An example of this natural immunoregulation occurs in pregnant mammals - the fetus expresses an immunoregulatory enzyme called indoleamine 2,3-dioxygenase (IDO). IDO expression stops the fetus from being attacked by the mother's immune system (Munn, Zhou et al. 1998). Essentially these enzymes work by breaking down amino acids to create a low nutrient environment for immune cells. The low nutrient environment starves the cells and causes their growth and function to slow. This is highlighted by the fact that the first symptomatic effect of protein malnutrition is acute immunodeficiency. My research into the discovery and characterization of small molecule drugs which will mimic natural immunosuppression mechanisms will drastically help suppress and treat unnecessary inflammatory diseases and prevent unnecessary side effects.
Munn, D. H., M. Zhou, et al. (1998). "Prevention of allogeneic fetal rejection by tryptophan catabolism." Science 281(5380): 1191-3.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
201573
Name
Ogloff Nadya A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Borrelidin: a novel therapeutic agent for treatment of inflammatory diseases.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Models; Cell Culture; Cytokines; Drug Development; Inflammatory Disease; Molecular Biology; Pharmacokinetics; Real Time Pcr; Signal Transduction
Abstract
Inflammation is the body's normal physiological response to injury, infection, or foreign substances. Although the ability to mount an inflammatory response is essential for survival, uncontrolled or excessive inflammatory responses damage tissues, cause organ dysfunction, and require clinical intervention. Despite the fact there have been advances in anti-inflammatory therapies over the years, long term use of steroidal and non-steroidal anti-inflammatory drugs (NSAIDS) are limited due to drug-induced toxicities such as stomach ulcer, gastric erosion, exacerbation of asthma and nephrotoxicity. Therefore, the identification of novel agents that can effectively suppress inflammatory responses without associated long term toxicities for treatment of chronic inflammatory diseases represents a major unmet medical need. To identify new anti-inflammatory drugs, we looked to nature for inspiration. One of the key ways that the body controls inflammation is through the expression of immunoregulatory enzymes. An example of this natural immunoregulation occurs in pregnant mammals - the fetus expresses an immunoregulatory enzyme called indoleamine 2,3-dioxygenase (IDO). IDO expression stops the fetus from being attacked by the mother's immune system (Munn, Zhou et al. 1998). Essentially these enzymes work by breaking down amino acids to create a low nutrient environment for immune cells. The low nutrient environment starves the cells and causes their growth and function to slow. This is highlighted by the fact that the first symptomatic effect of protein malnutrition is acute immunodeficiency. My research into the discovery and characterization of small molecule drugs which will mimic natural immunosuppression mechanisms will drastically help suppress and treat unnecessary inflammatory diseases and prevent unnecessary side effects.
Munn, D. H., M. Zhou, et al. (1998). "Prevention of allogeneic fetal rejection by tryptophan catabolism." Science 281(5380): 1191-3.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ogloff, Nadya A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~